AstraZeneca and Daiichi Sankyo's Enhertu approved in EU for advanced breast cancer treatment

From Nasdaq: 2025-04-04 02:19:00

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union for advanced breast cancer treatment in patients who have already tried endocrine therapy. The approval follows positive results from the DESTINY-Breast06 Phase III trial, showing Enhertu’s superiority over chemotherapy with a median progression-free survival of more than one year. Enhertu is a HER2-directed antibody drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo, approved in over 75 countries for HER2-low metastatic breast cancer. Regulatory applications are pending in Japan and other countries. Visit rttnews.com for more health news.



Read more at Nasdaq: AstraZeneca And Daiichi Sankyo’s Enhertu Approved In EU For Advanced Breast Cancer Treatment